Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents

Clin Pharmacokinet. 2021 May;60(5):563-567. doi: 10.1007/s40262-021-00987-2. Epub 2021 Mar 2.

Authors

Mohamed Elmeliegy¹, Chandrasekhar Udata², Ken Liao³, Donghua Yin³

Affiliations

¹ Clinical Pharmacology, Global Product Development, Pfizer Inc., 10555 Science Center Dr., San Diego, CA, 92121, USA. Mohamed.Elmeliegy@pfizer.com.
² Clinical Pharmacology, Alexion Pharmaceuticals Inc, Cambridge, MA, USA.
³ Clinical Pharmacology, Early Clinical Development, Pfizer Inc, San Diego, CA, USA.

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / adverse effects
Biological Factors
Biological Products*
Humans

Substances

Antineoplastic Agents
Biological Factors
Biological Products